Specific HLA Types are Associated with Antiepileptic Drug-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Japanese Subjects
-
- Nahoko Kaniwa
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo158-8501, Japan
-
- Emiko Sugiyama
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo158-8501, Japan
-
- Yoshiro Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo158-8501, Japan
-
- Kouichi Kurose
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo158-8501, Japan
-
- Keiko Maekawa
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo158-8501, Japan
-
- Ryuichi Hasegawa
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo158-8501, Japan
-
- Hirokazu Furuya
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Hiroko Ikeda
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Yukitoshi Takahashi
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Masaaki Muramatsu
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Masahiro Tohkin
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Takeshi Ozeki
- Center for Genomic Medicine, RIKEN, Yokohama, Japan
-
- Taisei Mushiroda
- Center for Genomic Medicine, RIKEN, Yokohama, Japan
-
- Michiaki Kubo
- Center for Genomic Medicine, RIKEN, Yokohama, Japan
-
- Naoyuki Kamatani
- Center for Genomic Medicine, RIKEN, Yokohama, Japan
-
- Masamichi Abe
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Akiko Yagami
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Mayumi Ueta
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Chie Sotozono
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Shigeru Kinoshita
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Zenro Ikezawa
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Kayoko Matsunaga
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
-
- Michiko Aihara
- The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
この論文をさがす
説明
This preliminary study investigated genomic biomarkers for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), related to three antiepileptic drugs, zonisamide, phenobarbital and phenytoin.HLA class I and HLA-DRB1 loci were genotyped for Japanese patients with zonisamide-, phenobarbital- or phenytoin-induced SJS/TEN (n = 12, 8 and 9, respectively) and for healthy Japanese volunteers (n = 2878).Carrier frequencies of HLA-A*02:07 in patients with zonisamide-induced SJS/TEN and in the general Japanese population were 41.7 and 6.81%, respectively. Carrier frequencies of HLA-B*51:01 in patients with phenobarbital- and phenytoin-induced SJS/TEN and in controls were 75.0, 55.6 and 15.2%, respectively. HLA-A*02:07 and HLA-B*51:01, in a dominant model, were significantly associated with zonisamide- and phenobarbital-induced SJS/TEN, respectively (Pc = 0.0176 and 0.0042, respectively).Our data suggest that HLA-A*02:07 and HLA-B*51:01 are potential biomarkers for zonisamide- and phenobarbital-induced SJS/TEN, respectively, in Japanese individuals.
収録刊行物
-
- Pharmacogenomics
-
Pharmacogenomics 14 (15), 1821-1831, 2013-11
Informa UK Limited
